+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Progressive Supranuclear Palsy - Pipeline Review, H1 2020

  • PDF Icon

    Drug Pipelines

  • 113 Pages
  • June 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5130315
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H1 2020, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 8, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Progressive Supranuclear Palsy - Overview
  • Progressive Supranuclear Palsy - Therapeutics Development
  • Progressive Supranuclear Palsy - Therapeutics Assessment
  • Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
  • Progressive Supranuclear Palsy - Drug Profiles
  • Progressive Supranuclear Palsy - Dormant Projects
  • Progressive Supranuclear Palsy - Discontinued Products
  • Progressive Supranuclear Palsy - Product Development Milestones
  • Appendix

List of Tables
  • Number of Products under Development for Progressive Supranuclear Palsy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by AbbVie Inc, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by Alterity Therapeutics Ltd, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by Aprinoia Therapeutics Inc, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by Arvinas Inc, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by AZTherapies Inc, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by Cerebrum Therapeutics Inc, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by Declion Pharmaceuticals Inc, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by EmeraMed Ltd, H1 2020
  • Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, H1 2020
  • Progressive Supranuclear Palsy - Dormant Projects, H1 2020
  • Progressive Supranuclear Palsy - Discontinued Products, H1 2020

List of Figures
  • Number of Products under Development for Progressive Supranuclear Palsy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc
  • Alterity Therapeutics Ltd
  • AlzProtect SAS
  • Aprinoia Therapeutics Inc
  • Arvinas Inc
  • Asceneuron SA
  • AZTherapies Inc
  • Cerebrum Therapeutics Inc
  • Cortice Biosciences Inc
  • Declion Pharmaceuticals Inc
  • EmeraMed Ltd
  • Merck & Co Inc
  • NeuroTau Inc
  • New Amsterdam Sciences Inc
  • Pinteon Therapeutics Inc
  • Prothena Corp Plc
  • Retrotope Inc
  • TauC3 Biologics Ltd
  • TauRx Therapeutics Ltd
  • UCB SA
  • Voyager Therapeutics Inc